Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;22(7):965-972.
doi: 10.1111/ddg.15433. Epub 2024 May 22.

SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest

María José Valencia López  1 , Anna Meineke  1 , Brigitte Stephan  1 , Stephan Jeff Rustenbach  1 , Anne Kis  1 , Diamant Thaçi  2 , Ulrich Mrowietz  3 , Kristian Reich  1 , Petra Staubach-Renz  4 , Ralph von Kiedrowski  5 , Henriette Bogena  1 , Matthias Augustin  1
Affiliations

SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest

María José Valencia López et al. J Dtsch Dermatol Ges. 2024 Jul.

Abstract

Background: Limited data exist on the characteristics of SARS-CoV-2 infections in German patients with psoriasis or psoriasis arthritis (PsA). This study analyses COVID-19 prevalence and severity of symptoms in these patients.

Patients and methods: Participants of the German registries PsoBest and CoronaBest were surveyed in February 2022. Descriptive analyses were conducted.

Results: 4,818 patients were included in the analysis, mean age of 56.4 years. Positive SARS-CoV-2 tests were reported by 737 (15.3%) patients. The most frequently reported acute symptoms were fatigue (67.3%), cough (58.8%), and headache (58.3%). Longer-lasting symptoms after COVID-19 were reported by 231 of 737 patients after the acute phase. For most patients (92.9%), systemic treatment for their psoriasis or PsA was not modified during the pandemic. Patients positively tested for SARS-CoV-2 were younger on average and had more often changes in the therapy of psoriasis than negatively tested patients (8.5% vs. 5.4%).

Conclusions: In this cohort of patients with psoriasis or PsA undergoing systemic treatment, SARS-CoV-2 infections were common but less frequent than in the general German population. No risk signals for more severe COVID-19 or increased infection rates were observed in the patients. In addition, systemic treatments remained largely unchanged, so that no risks can be attributed to these therapies.

Keywords: COVID‐19; CoronaBest; PsoBest; SARS‐CoV‐2; psoriasis; registry.

PubMed Disclaimer

References

REFERENCES

    1. Solomon M, Liang C. Human coronaviruses: The emergence of SARS‐CoV‐2 and management of COVID‐19. Virus Res. 2022;319:198882.
    1. Robert Koch‐Institut (2022) Täglicher Lagebericht des RKI zur Coronavirus‐Krankheit –2019 (COVID‐19). 31.03.2022 – Aktualisierter Stand für Deutschland. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsb... [Last accessed May 10, 2023].
    1. Zawilska JB, Lagodzinski A, Berezinska M. COVID‐19: from the structure and replication cycle of SARS‐CoV‐2 to its disease symptoms and treatment. J Physiol Pharmacol. 2021;72.
    1. Mantovani A, Morrone MC, Patrono C et al. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022;29:1891‐1900.
    1. Soriano JB, Murthy S, Marshall JC et al. A clinical case definition of post‐COVID‐19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102‐e107.